S-777469

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H27FN2O4
Molecular Weight	414.4699
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC1=C(C)C=C(C(=O)NC2(CCCCC2)C(O)=O)C(=O)N1CC3=CC=C(F)C=C3

InChI

InChIKey=JIYXOJFSPOFZPY-UHFFFAOYSA-N

InChI=1S/C23H27FN2O4/c1-3-19-15(2)13-18(20(27)25-23(22(29)30)11-5-4-6-12-23)21(28)26(19)14-16-7-9-17(24)10-8-16/h7-10,13H,3-6,11-12,14H2,1-2H3,(H,25,27)(H,29,30)

HIDE SMILES / InChI

Molecular Formula	C23H27FN2O4
Molecular Weight	414.4699
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00703573 | https://www.ncbi.nlm.nih.gov/pubmed/25721168 | https://adisinsight.springer.com/drugs/800025261

Shionogi developed S 777469 as a selective cannabinoid 2 receptor agonist for the atopic dermatitis treatment. This drug successfully completed phase II clinical trial, where was evaluate its safety and efficacy in patients with atopic dermatitis. However, information about the further development of S 777469 is not available.

Originator

Approval Year

PubMed

Title	Date	PubMed
S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission.	2015	25721168

Patents

Sample Use Guides

In Vivo Use Guide

S-777469 400 mg BID (two 200 mg tablets of S-777469 and two tablets of placebo BID)

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:19:28 GMT 2023` Edited by `admin` on `Fri Dec 15 16:19:28 GMT 2023`
Record UNII	88NI79737I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

S-777469

Common Name

English

Code System Code Type Description

PUBCHEM

57331749